Research & Development
-
Getty Images
AI’s next trick? Revealing new disease targets for drug R&D
A wave of AI-driven platforms bucks the traditional approach of hunting for new molecules and instead focuses on pinpointing the underlying cause of disease.
By Meagan Parrish • April 3, 2026 -
Getty Images
Will Pfizer’s Lyme disease gamble pay off or set the space back?
As the disease spreads into new regions, the urgency for prevention is growing.
By Kelly Bilodeau • April 1, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Getty Images
mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts
Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.
By Alexandra Pecci • March 31, 2026 -
Getty Images
Can Ocugen succeed where other gene therapy makers have struggled?
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.
By Meagan Parrish • March 27, 2026 -
Getty Images
Q&AHow former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.
By Jacob Bell • March 26, 2026 -
Getty Images
Mixed signals cloud the orphan drug market
The field is making gains despite regulatory inconsistency, but rising competition from obesity candidates and evolving global pressures could erode orphan drugs’ market share.
By Kelly Bilodeau • March 25, 2026 -
Getty Images
Women in biotech hit a leadership plateau as board barriers persist
A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.
By Alexandra Pecci • March 24, 2026 -
Getty Images
How AI is reshaping clinical trials
Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.
By Kelly Bilodeau • March 23, 2026 -
Permission granted by Gilead Sciences
Deep DiveGilead could potentially end HIV. But will it be able to?
After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.
By Meagan Parrish • March 20, 2026 -
Getty Images
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.
By Alexandra Pecci • March 19, 2026 -
Getty Images
As Chinese biotechs recognize their value, the bargain era may be over
Rising average upfront payments signal that buyers see value in Chinese assets.
By Kelly Bilodeau • March 18, 2026 -
Getty Images
Q&AVC sees early signs of a biotech market spring as long winter fades
The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.
By Michael Gibney • March 17, 2026 -
Courtesy of Novo Nordisk
Novo regained weight loss footing in the pill arena — but Lilly is coming
Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?
By Alivia Kaylor • March 13, 2026 -
Alamy
Keytruda’s reign continues; pharma’s megadeal drought
Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.
By PharmaVoice Staff • March 13, 2026 -
Permission granted by Merck & Co.
Keytruda and Padcev could become cancer’s power couple
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
By Alexandra Pecci • March 11, 2026 -
Getty Images
Executives want in, but researchers want out — how pharma’s US job picture is changing
While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.
By Alexandra Pecci • March 10, 2026 -
Alamy
The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.
By Kelly Bilodeau • March 9, 2026 -
Permission granted by Exact Sciences
Q&ACancer tests are becoming more precise and guiding pharma R&D
Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D.
By Michael Gibney • March 5, 2026 -
Sarah Silbiger via Getty Images
What 3 recent FDA rejections reveal about shifts inside the agency
The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.
By Alexandra Pecci • March 4, 2026 -
Paul Morigi / Getty Images via Getty Images
Inside the race to thwart the dramatic rise in early-onset colorectal cancer
The increasingly common disease still presents a major challenge in oncology.
By Kelly Bilodeau • March 4, 2026 -
Getty Images
J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
Spravato became a blockbuster despite ketamine’s dangerous abuse history, causing doctors to balance the real-world implications of its use.
By Michael Gibney • March 3, 2026 -
Getty Images
How does the FDA really feel about psychedelics? We could soon find out.
Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.
By Kelly Bilodeau • Feb. 23, 2026 -
Getty Images
No one-trick pony in oncology, Merck’s cancer footprint is expanding
The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.
By Meagan Parrish • Feb. 20, 2026 -
Getty Images
Pharma could be on the cusp of finally breaking the blood-brain barrier
Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground.
By Kelly Bilodeau • Feb. 18, 2026 -
Getty Images
More drugmakers are turning to cancer combos. Will it help patients live longer?
Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.
By Kelly Bilodeau • Feb. 17, 2026
